Survival of patients with multiple primary malignancies: a study of 783 patients with gastrointestinal stromal tumor
Survival of patients with multiple primary malignancies: a study of 783 patients with gastrointestinal stromal tumor
复制标题
DOI：
10.1093/annonc/mdq078
复制
发表时间：
2010-10-01
影响因子：
50.5
通讯作者：
Trent, J. C.
中科院分区：
文献类型：
--
作者：
Pandurengan, R. K.;Dumont, A. G.;Trent, J. C.
背景资料：我们试图探讨胃肠道间质瘤（GIST）与其他原发性恶性肿瘤相关的患者的特点和生存率。患者和方法：从1995年至2007年，共783例GIST患者被确定。其他原发性肿瘤包括不认为转移、浸润或GIST复发的肿瘤，也不包括非黑色素瘤皮肤癌。性别，诊断时的年龄，诊断后的随访时间，和死亡的数据collected.Results：783例GIST，153（20%）被确定为至少有一个额外的主要。有额外原发灶的患者更常见于男性（男：女1.5与1.3）和老年人（66岁与53岁）。更多的患者在GIST之前（134）比之后（52）诊断出另一种癌症。在GIST之前观察到的主要癌症是前列腺癌（25）、乳腺癌（12）、食管癌（9）和肾癌（7）以及黑色素瘤（6）。GIST后肺（5例）和肾（5例）原发灶最常见。GIST前有原发灶的患者5年生存率为68%，GIST后有原发灶的患者为61%，单纯GIST患者为58%，除GIST外有两个或两个以上原发灶的患者为49%（P = 0.002）。GIST合并两种或两种以上其他癌症患者的中位5年生存率较低。GIST患者的其他恶性肿瘤的病因和临床意义应进行调查。
Background: We sought to investigate the characteristics and survival rate of patients with gastrointestinal stromal tumor (GIST) associated with other primary malignancies.Patients and methods: A total of 783 patients with GIST were identified from 1995 to 2007. Additional primaries included tumors not considered metastasis, invasion, or recurrence of GIST, nor non-melanoma skin cancer. Data on gender, age at diagnosis, follow-up time after diagnosis, and death were collected.Results: Of the 783 patients with GIST, 153(20%) were identified with at least one additional primary. Patients with additional primaries were more often men (M : F 1.5 versus 1.3) and older (66 versus 53 years). More patients had another cancer diagnosed before (134) than after (52) GIST. Primaries observed before GIST were cancers of the prostate (25), breast (12), esophagus (9), and kidney (7) and melanoma (6). Lung (5) and kidney (5) primaries were the most frequent after GIST. The 5-year survival was 68% for patients with primaries before GIST, 61% for patients with primaries after GIST, 58% for patients with GIST only, and 49% for patients with two or more primaries in addition to GIST (P = 0.002).Conclusions: Approximately 20% of patients with GIST develop other cancers. Inferior median 5-year survival was observed in patients with GIST with two or more other cancers. The etiology and clinical implications of other malignancies in patients with GIST should be investigated.